

November 13, 2019

To
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Sub: **Outcome of Board Meeting held on November 13, 2019**

Dear Sir/Madam,

We wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. November 13, 2019, have


1. Considered & approved the Standalone and Consolidated Un-audited financial results of the company for the quarter/ half year ended September 30, 2019.

In this connection please find enclosed the copy of Un-audited Standalone and Consolidated financial Results of the Company for the quarter/half year ended September 30, 2019 along with Limited Review Report by the Statutory Auditors of the Company.

The meeting commenced at 11:00 A.M. and concluded at 8:00 P.M
The above is for information and dissemination to the public at large.

Thanking You,

Yours Faithfully,
For Kilitch Drugs (India) Limited


Mukund Mehta
Managing Director
DIN:00147876



Encl: as above



AJIT M. GHELANI
B.Com (Hons), F.C.A., GRAD. C.W.A.

CHINTAN A. GHELANI
B.Com (Hons), F.C.A., C.S

To,
The Board of Directors
Kilitch Drugs (India) Limited


LIMITED REVIEW REPORT ON THE UNAUDITED STANDALONE RESULTS OF KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2019

1. We have reviewed the accompanying statement of unaudited standalone financial results of KILITCH DRUGS (INDIA) LIMITED (the 'Company') for the quarter and half year ended September 30, 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (IND AS 34) "Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company

Chartered Accountants

FRN: 103173W



Chintan Ghelani

Partner

Membership No.: 104391



ICAI UDIN: 19104391AAAAEB5061

Place : Mumbai

Dated : 13th November, 2019

Encl: Standalone Unaudited financial results for the quarter and half year ended 30th September, 2019

KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2019

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

(Rs.in Lakhs)

| Sr. No. | Particulars | STANDALONE | | | | | |
|-----------|--|--------------------|-----------------|-----------------|------------------|-----------------|------------------|
| | | Three months ended | | | Six months ended | | Year Ended |
| | | 30/09/2019 | 30/06/2019 | 30/09/2018 | 30/09/2019 | 30/09/2018 | 31/03/2019 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited | |
| 1 | Income from operations | | | | | | |
| | Net Sales/ Income from operations | 1,777.38 | 1,198.27 | 2,672.00 | 2,975.65 | 5,469.34 | 9,641.76 |
| | Other Income | 92.05 | 175.48 | 188.69 | 267.53 | 425.46 | 451.82 |
| | Total Income from Operations | 1,869.43 | 1,373.75 | 2,860.69 | 3,243.18 | 5,894.80 | 10,093.58 |
| 2 | Expenses | | | | | | |
| | (a) Cost of Materials Consumed | 817.52 | 883.08 | 1,635.05 | 1,700.60 | 3,400.58 | 5,316.22 |
| | (b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade | 153.49 | (105.07) | 18.42 | 48.42 | (36.89) | (17.70) |
| | (c) Employee Benefit Expenses | 138.92 | 132.58 | 143.74 | 271.50 | 280.11 | 522.89 |
| | (d) Finance Cost | 16.44 | 15.10 | - | 31.54 | - | 37.91 |
| | (e) Depreciation and Amortisation Expenses | 23.75 | 22.48 | 29.31 | 46.23 | 55.32 | 120.38 |
| | (f) Export Product Registration/Commission | 85.99 | 124.88 | 242.02 | 210.87 | 306.08 | 683.93 |
| | (g) Other Expenses | 388.57 | 210.99 | 179.77 | 599.56 | 743.12 | 1,477.48 |
| | Total Expenses | 1,624.68 | 1,284.04 | 2,248.31 | 2,908.72 | 4,748.31 | 8,141.11 |
| 3 | Profit / (Loss) before Exceptional items (1-2) | 244.75 | 89.71 | 612.38 | 334.46 | 1,146.48 | 1,952.47 |
| 4 | Exceptional Items | - | - | - | - | - | - |
| 5 | Profit / (Loss) from ordinary activities before tax (3+4) | 244.75 | 89.71 | 612.38 | 334.46 | 1,146.48 | 1,952.47 |
| 6 | Tax Expenses: | | | | | | |
| | Current Tax | 42.90 | 4.65 | 146.88 | 47.55 | 206.00 | 424.08 |
| | Deferred Tax | (8.47) | 20.62 | 16.85 | 12.15 | 74.92 | 51.66 |
| 7 | Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6) | 210.32 | 64.44 | 448.65 | 274.76 | 865.56 | 1,476.73 |
| 8 | Other Comprehensive Income (after tax) | (27.44) | (37.21) | (108.05) | (64.65) | (137.64) | (105.69) |
| 9 | Total Comprehensive Income (after taxes) (7+8) | 182.88 | 27.23 | 340.60 | 210.11 | 727.92 | 1,371.04 |
| 10 | Paid-Up equity share capital (Face Value Rs 10 per share) | 1,543.42 | 1,541.75 | 1,535.52 | 1,543.42 | 1,535.52 | 1,535.52 |
| 11 | Other Equity | | | | | | 13,572.84 |
| 12 | Earnings per share | | | | | | |
| | (a) Basic (not annualised) | 1.36 | 0.42 | 3.20 | 1.78 | 6.24 | 10.06 |
| | (b) Diluted (not annualised) | 1.36 | 0.42 | 3.20 | 1.78 | 5.92 | 10.06 |

Notes:

- The above unaudited results as reviewed by the Audit Committee have been taken on record by the Board of Directors at their meeting held on 13th November, 2019.
- The statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable..
- The company has issued 16,709 Equity Shares under the ESOP scheme at an exercise price of Rs. 10 per equity share during the quarter ended 30th September, 2019
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The IND AS 115 Revenue from Contract with customers, mandatory for reporting periods beginning on or after April 1, 2018, replaces the existing revenue recognition requirements. The application of IND AS 115 has not impacted the company's accounting for recognition of revenue.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

For and on behalf of the Board of Directors

Mukund P. Mehta

Mukund P. Mehta
Managing Director

Place: Mumbai
Date: 13th November, 2019




KILITCH DRUGS (INDIA) LIMITED

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Rs.in Lakhs)

| Particulars | STANDALONE | |
|--------------------------------|---|-----------------------------------|
| | As at 30th September, 2019 Unaudited | As at 31st March, 2019 Audited |
| ASSETS | | |
| Non-current assets | | |
| Property, Plant and Equipment | 764.55 | 778.91 |
| Other Intangible Assets | 3.71 | 2.90 |
| Financial assets | | |
| - Investments | 7,028.09 | 7,123.66 |
| - Loans/Advances | 3,035.45 | 2,772.80 |
| Deferred tax assets (Net) | 90.97 | 103.13 |
| (A) | 10,922.78 | 10,781.40 |
| Current Assets | | |
| Inventories | 353.36 | 471.58 |
| Financial assets | | |
| - Investments | 3,147.54 | 2,841.62 |
| - Trade Receivables | 2,292.79 | 2,314.53 |
| - Cash & Bank Balances | 152.19 | 407.21 |
| - Other Financial Assets | 9.87 | 11.04 |
| Other Current Assets | 638.36 | 375.43 |
| (B) | 6,594.11 | 6,421.41 |
| TOTAL (A + B) | 17,516.89 | 17,202.81 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| Equity Share Capital | 1,543.42 | 1,535.52 |
| Other Equity | 13,696.60 | 13,572.84 |
| (A) | 15,240.02 | 15,108.36 |
| Non-Current liabilities | | |
| Provisions | 41.18 | 41.34 |
| Current liabilities | | |
| Financial Liabilities | | |
| - Borrowings | 1,279.14 | 935.71 |
| - Trade Payables | | |
| Micro and Small Enterprises | - | - |
| Others | 323.32 | 546.90 |
| - Other Financial Liabilities | 181.10 | 88.07 |
| Provisions | 76.42 | 68.15 |
| Current Tax Liabilities [Net] | 166.10 | 171.83 |
| Other Current Liabilities | 209.60 | 242.45 |
| (B) | 2,276.87 | 2,094.45 |
| TOTAL (A+B) | 17,516.89 | 17,202.81 |

For and on behalf of the Board of Directors


Mukund Mehta
 Managing Director



Place: Mumbai


Dated: 13th November, 2019

KILITCH DRUGS (INDIA) LIMITED
UNAUDITED STANDALONE CASH FLOW STATEMENT

Rs. (In Lacs)

| Particulars | Half year ended 30th September, 2019 | | Financial year ended 31st March, 2019 | |
|---|--------------------------------------|-----------------|---------------------------------------|-------------------|
| | Unaudited | | Audited | |
| A. CASH FLOW FROM OPERATING ACTIVITIES | | | | |
| Net Profit / (Loss) before extraordinary items and tax | | 334.47 | | 1,952.48 |
| <u>Adjustments for:</u> | | | | |
| Depreciation and amortisation | 46.23 | | 120.38 | |
| Interest income | (89.36) | | (75.69) | |
| Dividend income | (5.61) | | (23.94) | |
| (Profit)/Loss on sale of Investments | (124.38) | | (240.71) | |
| Sundry Balances written back | - | | (17.51) | |
| Provision for Gratuity & Leave Encashment | - | | 13.15 | |
| Share based payments to Employees | 6.68 | | - | |
| Provision for Doubtful Debts/Advances | (37.74) | | (126.06) | |
| (Profit) / Loss from Investment in Partnership Firm | - | | 0.27 | |
| Net unrealised exchange (gain) / loss | (36.31) | (240.48) | 69.02 | (281.09) |
| Operating profit / (loss) before working capital changes | | 93.99 | | 1,671.39 |
| <u>Changes in working capital:</u> | | | | |
| <u>Operating Assets:</u> | | | | |
| Inventories | 118.22 | | (191.94) | |
| Trade receivables | 95.80 | | (185.48) | |
| Other current assets | (262.93) | | 9.21 | |
| Deposits and Advances | 6.88 | | (11.53) | |
| Other Financial Assets | 1.17 | | 19.87 | |
| <u>Operating Liabilities:</u> | | | | |
| Trade payables | (223.58) | | (201.52) | |
| Other current liabilities | (32.85) | | 42.36 | |
| Short Term Provisions | 8.12 | (289.17) | 6.89 | (512.14) |
| Gross cash flow from / (used in) operating activities | | (195.18) | | 1,159.25 |
| Less : Direct Taxes (Paid) / refunded | | (53.28) | | (417.65) |
| Net cash flow from / (used in) operating activities | | (248.46) | | 741.60 |
| B. CASH FLOW FROM INVESTING ACTIVITIES | | | | |
| Capital expenditure on fixed assets, including capital advances | (32.69) | | (167.02) | |
| Loans/Advances to Related Parties | (269.53) | | (2,402.48) | |
| Proceeds (Net) from the sale of Current investments | (305.92) | | 299.96 | |
| Proceeds (Net) from the sale of long-term investments: | | | | |
| - Subsidiaries | - | | - | |
| - Others | 155.29 | | (99.40) | |
| Movement in other Bank balance | - | | 78.97 | |
| Interest received | 89.36 | | 75.69 | |
| Dividend received | 5.61 | | 23.94 | |
| | | (357.88) | | (2,190.36) |
| Net cash flow from / (used in) investing activities (B) | | (357.88) | | (2,190.36) |
| C. CASH FLOW FROM FINANCING ACTIVITIES | | | | |
| Proceeds from Shares issued [incl. ESOPs] | 7.89 | | 24.50 | |
| Proceeds from Borrowings [Net of Repayments] | 343.43 | | 853.24 | |
| Money received against warrants | - | | 685.84 | |
| Dividends paid (Inclusive of tax on Dividend) | - | | (95.04) | |
| Net cash flow from / (used in) financing activities (C) | | 351.32 | | 1,468.55 |
| Net increase / (decrease) in Cash and cash equivalents (A+B+C) | | (255.02) | | 19.78 |
| Cash and cash equivalents at the beginning of the period/year | | 407.21 | | 387.43 |
| Cash and cash equivalents at the end of the period/year | | 152.19 | | 407.21 |
| Cash and cash equivalents at the end of the period/year * | | | | |
| * Comprises: | | | | |
| (a) Cash on hand | | 0.19 | | 45.16 |
| (b) Balances with banks | | | | |
| (i) In current accounts | | 63.93 | | 273.98 |
| (ii) In earmarked accounts | | 88.07 | | 88.07 |
| | | 152.19 | | 407.21 |

For and on behalf of the Board of Directors


Mukund Mehta
Managing Director



Place: Mumbai
Dated: 13th November, 2019

AJIT M. GHELANI
B.Com (Hons), F.C.A., GRAD. C.W.A.

CHINTAN A. GHELANI
B.Com (Hons), F.C.A., C.S

LIMITED REVIEW REPORT

To,
The Board of Directors
Kilitch Drugs India Limited

**LIMITED REVIEW REPORT OF THE UNAUDITED CONSOLIDATED RESULTS OF
KILITCH DRUGS INDIA LIMITED FOR THE QUARTER AND HALF YEAR ENDED 30th
SEPTEMBER, 2019**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs India Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30th September, 2019 and year to date from 1st April, 2019 to 30th September, 2019 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared by in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and the accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

List of Subsidiaries:

1. Monarchy Healthserve Private Limited
2. Kilitch Estro Biotech PLC – Foreign Subsidiary




A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

5. (a) The accompanying Statement includes interim financial results and other financial information of one subsidiary which reflects, total assets of Rs. 2,601.04 Lakhs as at 30th September 2019, total revenue of Rs. 201.18 Lakhs and Rs. 202.79 Lakhs, total net loss after tax of Rs. 11.86 Lakhs and Rs. 35.38 Lakhs for the quarter ended 30th September, 2019 and for the period from 1st April, 2019 to 30th September, 2019 respectively and net cash inflow of Rs. 1.36 Lakhs for the period from 1st April, 2019 to 30th September, 2019 which have been reviewed by us.

(b) The Statement includes interim financial results and other financial information in respect of one subsidiary which reflects total assets of Rs. 3,811.59 Lakhs as at 30th September 2019 and net cash outflow of Rs. 260.88 Lakhs for the period from 1st April, 2019 to 30th September, 2019 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management. Our conclusion on the Statement is not modified in respect of the above matter.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statement referred in paragraph 5(b) above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M. Ghelani & Company
Chartered Accountants
Firm Registration No : 103173W


Chintan Ghelani
Partner
Membership No.: 104391



Place : Mumbai
Date : 13th November, 2019

UDIN :19104391AAAAED6888

KILITCH DRUGS (INDIA) LIMITED
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2019

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022- 61214100, Email id: info@killitch.com, Website: www.killitch.com
CIN:L24239MH1992PLC066718

(Rs. in Lakhs)

| Sr. No. | Particulars | CONSOLIDATED | | | | | |
|---------|--|--------------------|-----------------|-----------------|-----------------|-----------------|------------------|
| | | Three Months Ended | | | Half Year Ended | | Year Ended |
| | | 30/09/2019 | 30/06/2019 | 30/09/2018 | 30/09/2019 | 30/09/2018 | 31/03/2019 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited | |
| 1 | Income From Operations | | | | | | |
| | Net Sales/Income from Operations | 1,533.51 | 1,043.19 | 2,682.09 | 2,576.70 | 5,490.61 | 8,248.99 |
| | Other Income | 58.63 | 137.79 | 192.16 | 196.42 | 429.83 | 400.40 |
| | Total Income from Operations | 1,592.14 | 1,180.98 | 2,874.25 | 2,773.12 | 5,920.44 | 8,649.39 |
| 2 | Expenses | | | | | | |
| | Cost of Materials Consumed | 698.79 | 748.97 | 1,636.09 | 1,447.76 | 3,403.63 | 4,834.51 |
| | Variation in inventories of finished goods, work-in-progress and Stock-in-Trade | 37.78 | (105.07) | 18.42 | (67.29) | (36.89) | (17.70) |
| | Employee Benefit Expenses | 139.86 | 133.44 | 145.42 | 273.30 | 283.58 | 528.37 |
| | Finance Cost | 16.44 | 15.10 | - | 31.54 | - | 37.91 |
| | Depreciation and Amortisation Expenses | 45.08 | 43.63 | 50.49 | 88.71 | 97.68 | 205.11 |
| | Export Product Registration/Commission | 85.99 | 124.88 | 242.02 | 210.87 | 306.08 | 683.93 |
| | Other expenses | 399.94 | 214.11 | 197.33 | 614.05 | 770.50 | 1,518.60 |
| | Total Expenses | 1,423.88 | 1,175.06 | 2,289.77 | 2,598.94 | 4,824.58 | 7,790.73 |
| 3 | Profit/(Loss) before Exceptional items (1-2) | 168.26 | 5.92 | 584.48 | 174.18 | 1,095.86 | 858.66 |
| 4 | Exceptional Items | - | - | - | - | - | - |
| 5 | Profit/(Loss) from ordinary activities before tax (3+4) | 168.26 | 5.92 | 584.48 | 174.18 | 1,095.86 | 858.66 |
| 6 | Less : Tax Expenses | | | | | | |
| | Current Income Tax | 42.90 | 4.65 | 146.88 | 47.55 | 206.00 | 424.08 |
| | Deferred Tax | (8.41) | 20.62 | 16.85 | 12.21 | 74.92 | 51.60 |
| 7 | Net Profit/(Loss) after tax for the period from continuing operations (5-6) | 133.77 | (19.35) | 420.75 | 114.42 | 814.94 | 382.98 |
| 8 | Other Comprehensive Income (after Tax) | (27.44) | (37.21) | (108.05) | (64.65) | (137.64) | (105.69) |
| 9 | Total Comprehensive Income (after taxes) (7+8) | 106.33 | (56.56) | 312.70 | 49.77 | 677.30 | 277.29 |
| 10 | Net Profit / (Loss) attributable to | | | | | | |
| | a) Owner of the Company | 133.77 | (19.35) | 420.75 | 114.42 | 814.94 | 382.98 |
| | b) Non Controlling interest | - | - | - | - | - | - |
| 11 | Other Comprehensive Income attributable to | | | | | | |
| | a) Owner of the Company | (27.44) | (37.21) | (108.05) | (64.65) | (137.64) | (105.69) |
| | b) Non Controlling interest | - | - | - | - | - | - |
| 12 | Total income attributable to | | | | | | |
| | a) Owner of the Company | 106.33 | (56.56) | 312.70 | 49.77 | 677.30 | 277.29 |
| | b) Non Controlling interest | - | - | - | - | - | - |
| 13 | Paid-Up equity share capital (Face Value Rs. 10 per share) | 1,543.42 | 1,541.75 | 1,535.52 | 1,543.42 | 1,535.52 | 1,535.52 |
| 14 | Other Equity | | | | | | 10,570.21 |
| 15 | Earning per share | | | | | | |
| | (a) Basic (not annualised) | 0.87 | (0.13) | 3.01 | 0.74 | 5.88 | 2.61 |
| | (b) Diluted (not annualised) | 0.87 | (0.13) | 3.01 | 0.74 | 5.61 | 2.61 |

Notes:

- The above unaudited results as reviewed by the Audit Committee have been taken on record by the Board of Directors at their meeting held on 13th November, 2019.
- The statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable..
- The company has issued 16,709 Equity Shares under the ESOP scheme at an exercise price of Rs. 10 per equity share during the quarter ended 30th September, 2019
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The IND AS 115 Revenue from Contract with customers, mandatory for reporting periods beginning on or after April 1, 2018, replaces the existing revenue recognition requirements. The application of IND AS 115 has not impacted the Group's accounting for recognition of revenue.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place: Mumbai
Date: 13th November, 2019



For and on behalf of the Board of Directors

Mukund P. Mehta
Mukund P. Mehta
Managing Director



KILITCH DRUGS (INDIA) LIMITED

UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2019

(Rs. In Lacs)

| Particulars | As at 30th September, 2019 Unaudited | As at 31st March, 2019 Audited |
|--|---|-----------------------------------|
| ASSETS | | |
| Non-current assets | | |
| Property, plant and equipment | 876.16 | 851.21 |
| Capital work-in-progress | 2,205.71 | 2,025.28 |
| Other Intangible assets | 2,320.71 | 2,362.03 |
| Financial assets | | |
| - Investments | 2,406.39 | 2,501.96 |
| - Loans/Advances | 28.87 | 34.26 |
| Deferred tax assets (Net) | 91.36 | 103.57 |
| (A) | 7,929.20 | 7,878.31 |
| Current assets | | |
| Inventories | 469.07 | 471.58 |
| Financial assets | | |
| - Investments | 3,147.54 | 2,841.62 |
| - Trade and other receivables | 2,108.36 | 1,943.59 |
| - Cash and cash equivalents | 279.46 | 794.01 |
| - Other Financials Assets | 9.87 | 56.00 |
| Other current assets | 891.52 | 381.03 |
| (B) | 6,905.82 | 6,487.84 |
| TOTAL (A + B) | 14,835.02 | 14,366.14 |
| Equity | | |
| Equity Share capital | 1,543.42 | 1,535.52 |
| Other equity | 10,534.35 | 10,570.21 |
| Equity attributable to the owners | 12,077.77 | 12,105.73 |
| Non-controlling interest | 212.93 | 209.66 |
| (A) | 12,290.70 | 12,315.39 |
| Liabilities | | |
| Non - Current Liabilities | | |
| Provisions | 41.18 | 41.34 |
| Current liabilities | | |
| Financial liabilities | | |
| - Borrowings | 1,335.74 | 945.41 |
| - Trade Payables | | |
| Micro and Small Enterprises | - | - |
| Others | 389.36 | 434.63 |
| - Other financial liabilities | 181.10 | 88.07 |
| Provisions | 78.62 | 68.50 |
| Current tax Liabilities (net) | 166.10 | 171.83 |
| Other current liabilities | 352.22 | 300.97 |
| (B) | 2,544.32 | 2,050.75 |
| TOTAL (A+B) | 14,835.02 | 14,366.14 |

Place: Mumbai
Date: 13th November, 2019



For and on behalf of the Board of Directors

Mukund P. Mehta
Mukund P. Mehta
Managing Director



KILITCH DRUGS (INDIA) LIMITED

CONSOLIDATED UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON SEPTEMBER 30, 2019

Rs. (In Lacs)

| Particulars | Half year ended 30th September 2019 | | Financial year ended 31st March 2019 | |
|---|-------------------------------------|-----------------|--------------------------------------|-------------------|
| | UNAUDITED | | AUDITED | |
| A. CASH FLOW FROM OPERATING ACTIVITIES | | | | |
| Net Profit before extraordinary items and tax | | 174.18 | | 858.67 |
| <i>Adjustments for:</i> | | | | |
| Depreciation and amortisation | 88.71 | | 205.11 | |
| Interest income | (9.36) | | (16.36) | |
| Dividend income | (5.61) | | (23.94) | |
| (Profit)/Loss on sale of Investments | (124.38) | | (240.71) | |
| Share of (Profit)/ Loss from Partnership Firm | - | | 0.27 | |
| Sundry Balances written back | - | | (17.51) | |
| Share Based Payments to Employee | 6.68 | | - | |
| Provision for Gratuity & Leave Encashment | - | | 13.20 | |
| Loss on Sale of assets | - | | 0.07 | |
| Loss/(Profit) from Trading in Securities | - | | 12.24 | |
| Bad Debts / Provision for Doubtful Debts | (37.74) | | 254.44 | |
| Net unrealised exchange (gain) / loss | (36.31) | (118.01) | (0.24) | 186.57 |
| Operating profit / (loss) before working capital changes | | 56.17 | | 1,045.24 |
| <i>Changes in working capital:</i> | | | | |
| <i>Operating Assets:</i> | | | | |
| Inventories | 2.52 | | (191.94) | |
| Trade receivables | (89.99) | | (128.30) | |
| Other current assets | 46.13 | | 9.00 | |
| Deposits/Advances | (510.48) | | (12.71) | |
| Other Financial Assets | - | | (3.59) | |
| <i>Operating Liabilities:</i> | | | | |
| Trade payables | (45.27) | | (319.41) | |
| Other current liabilities | 51.25 | | 41.60 | |
| Provisions | 9.96 | (535.89) | 6.84 | (598.52) |
| Gross cash flow from / (used in) operating activities | | (479.72) | | 446.72 |
| Direct Taxes (Paid) / refunded | | (53.28) | | (417.63) |
| Net cash flow from / (used in) operating activities | | (533.00) | | 29.09 |
| B. CASH FLOW FROM INVESTING ACTIVITIES | | | | |
| Capital expenditure on fixed assets, including capital advances | (252.77) | | (1,902.17) | |
| Loans/Advances refunded | 5.39 | | - | |
| Proceeds/(Purchase) -(Net) of Current investments | (305.92) | | 287.73 | |
| (Purchase)/Sale (Net) of long-term investments: | | | | |
| - Others | 155.29 | | 97.33 | |
| Movement in other Bank balance | - | | 78.97 | |
| Interest received | 9.36 | | 16.36 | |
| Dividend received | 5.61 | | 23.94 | |
| | | (383.04) | | (1,397.86) |
| | | (383.04) | | (1,397.86) |
| Net cash flow from / (used in) investing activities (B) | | (383.04) | | (1,397.86) |
| C. CASH FLOW FROM FINANCING ACTIVITIES | | | | |
| Proceeds from Shares issued | 7.89 | | 704.98 | |
| Proceeds from Borrowings (Net of Repayments) | 390.33 | | 853.24 | |
| Proceeds from Minorities | 3.27 | | 222.35 | |
| Dividends paid (Inclusive of tax on Dividend) | - | | (95.04) | |
| Net cash flow from / (used in) financing activities (C) | | 401.49 | | 1,685.53 |
| Net increase / (decrease) in Cash and cash equivalents (A+B+C) | | (514.55) | | 316.75 |
| Cash and cash equivalents at the beginning of the year | | 794.01 | | 477.26 |
| Cash and cash equivalents at the end of the year | | 279.46 | | 794.01 |
| Cash and cash equivalents at the end of the year * | | | | |
| * Comprises: | | | | |
| (a) Cash on hand | | 0.50 | | 45.30 |
| (b) Balances with banks | | | | |
| (i) In current accounts | | 190.89 | | 660.64 |
| (ii) In earmarked accounts | | 88.07 | | 88.07 |
| | | 279.46 | | 794.01 |

Place: Mumbai
Date: 13th November, 2019



For and on behalf of the Board of Directors
Mukund P. Mehta
Managing Director

